{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:34:28Z","timestamp":1777577668360,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12325-022-02212-3","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T17:03:53Z","timestamp":1656176633000},"page":"3735-3748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Initiating or Switching to Insulin Degludec\/Insulin Aspart in Adults with Type\u00a02 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-0420","authenticated-orcid":false,"given":"Gregory R.","family":"Fulcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh J.","family":"Al-Jaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafauzy","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Nemencio A.","family":"Nicodemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Helene","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"2212_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S125\u201343.","DOI":"10.2337\/dc22-S009"},{"key":"2212_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s13300-014-0077-8","volume":"5","author":"WD Strain","year":"2014","unstructured":"Strain WD, Bluher M, Paldanius P. Clinical inertia in individualising care for diabetes: Is there time to do more in type\u00a02 diabetes? Diabetes Ther. 2014;5:347\u201354.","journal-title":"Diabetes Ther"},{"key":"2212_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.diabres.2014.05.005","volume":"105","author":"WD Strain","year":"2014","unstructured":"Strain WD, Cos X, Hirst M, et al. Time to do more: addressing clinical inertia in the management of type\u00a02 diabetes mellitus. Diabetes Res Clin Pract. 2014;105:302\u201312.","journal-title":"Diabetes Res Clin Pract"},{"key":"2212_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682\u20139.","journal-title":"Diabet Med"},{"key":"2212_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40262-016-0455-7","volume":"56","author":"H Haahr","year":"2017","unstructured":"Haahr H, Fita EG, Heise T. A review of insulin degludec\/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet. 2017;56:339\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"2212_CR6","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2337\/dc13-2908","volume":"37","author":"GR Fulcher","year":"2014","unstructured":"Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec\/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type\u00a02 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37:2084\u201390.","journal-title":"Diabetes Care"},{"key":"2212_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.diabres.2014.09.026","volume":"107","author":"S Kaneko","year":"2015","unstructured":"Kaneko S, Chow F, Choi DS, et al. Insulin degludec\/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type\u00a02 diabetes inadequately controlled on basal or pre-\/self-mixed insulin: a 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract. 2015;107:139\u201347.","journal-title":"Diabetes Res Clin Pract"},{"key":"2212_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/dme.12982","volume":"33","author":"E Franek","year":"2016","unstructured":"Franek E, Haluzik M, Canecki Varzic S, et al. Twice-daily insulin degludec\/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with type\u00a02 diabetes. Diabet Med. 2016;33:497\u2013505.","journal-title":"Diabet Med"},{"key":"2212_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/dom.12609","volume":"18","author":"HW Rodbard","year":"2016","unstructured":"Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG. Treatment intensification with an insulin degludec (IDeg)\/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type\u00a02 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab. 2016;18:274\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"2212_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4158\/EP15893.OR","volume":"22","author":"G Gerety","year":"2016","unstructured":"Gerety G, Bebakar WM, Chaykin L, et al. Treatment intensification with insulin degludec\/insulin aspart twice daily: randomized study to compare simple and step-wise titration algorithms. Endocr Pract. 2016;22:546\u201354.","journal-title":"Endocr Pract"},{"key":"2212_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/dme.13068","volume":"34","author":"IB Hirsch","year":"2017","unstructured":"Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K. Safety and efficacy of insulin degludec\/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with type 1 diabetes: 1-year results from a randomized clinical trial (BOOST\u00ae T1). Diabet Med. 2017;34:167\u201373.","journal-title":"Diabet Med"},{"key":"2212_CR12","unstructured":"Novo Nordisk A\/S. Ryzodeg summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002499\/WC500139011.pdf. Accessed 19 January 2022."},{"key":"2212_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/2230-8210.177416","volume":"20","author":"S Kalra","year":"2016","unstructured":"Kalra S, Baruah MP. Insulin degludec aspart: one-year real world experience. Indian J Endocrinol Metab. 2016;20:369\u201371.","journal-title":"Indian J Endocrinol Metab"},{"key":"2212_CR14","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s13300-021-01117-8","volume":"12","author":"F Shigiyama","year":"2021","unstructured":"Shigiyama F, Liu L, Nordahl H, Suzuki R, Yamamoto Y, Hirose T. A real-world, prospective, non-interventional study of adults with T2D switching to IDegAsp from Glargine U100 or U300 in Japan. Diabetes Ther. 2021;12:2405\u201321.","journal-title":"Diabetes Ther"},{"key":"2212_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12020-021-02887-8","volume":"74","author":"GR Fulcher","year":"2021","unstructured":"Fulcher GR, Jarlov H, Piltoft JS, et al. ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec\/insulin aspart in patients with type\u00a02 diabetes in real-world settings: rationale and design. Endocrine. 2021;74:530\u20137.","journal-title":"Endocrine"},{"key":"2212_CR16","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310:2191\u201394.","DOI":"10.1001\/jama.2013.281053"},{"key":"2212_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","volume":"36","author":"CM Apovian","year":"2019","unstructured":"Apovian CM, Okemah J, O\u2019Neil PM. Body weight considerations in the management of type\u00a02 diabetes. Adv Ther. 2019;36:44\u201358.","journal-title":"Adv Ther"},{"key":"2212_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jsps.2020.01.014","volume":"28","author":"K Al-Rubeaan","year":"2020","unstructured":"Al-Rubeaan K, Bana FA, Alruwaily FG, et al. Physicians\u2019 choices in the first- and second-line management of type\u00a02 diabetes in the Kingdom of Saudi Arabia. Saudi Pharm J. 2020;28:329\u201337.","journal-title":"Saudi Pharm J"},{"key":"2212_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/2230-8210.163171","volume":"19","author":"S Kalra","year":"2015","unstructured":"Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type\u00a02 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab. 2015;19:577\u201396.","journal-title":"Indian J Endocrinol Metab"},{"key":"2212_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4093\/dmj.2016.40.6.454","volume":"40","author":"Y Yang","year":"2016","unstructured":"Yang Y, Shin JA, Yang HK, et al. Reduction of sulfonylurea with the initiation of basal insulin in patients with inadequately controlled type\u00a02 diabetes mellitus undergoing long-term sulfonylurea-based treatment. Diabetes Metab J. 2016;40:454\u201362.","journal-title":"Diabetes Metab J"},{"key":"2212_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","volume":"9","author":"D Russell-Jones","year":"2007","unstructured":"Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799\u2013812.","journal-title":"Diabetes Obes Metab"},{"key":"2212_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3121\/cmr.2008.793","volume":"6","author":"I Hartman","year":"2008","unstructured":"Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6:54\u201367.","journal-title":"Clin Med Res"},{"key":"2212_CR23","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/dom.13261","volume":"20","author":"M Haluzik","year":"2018","unstructured":"Haluzik M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D, Rodbard HW. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: a pooled meta-analysis of phase III studies in patients with type\u00a02 diabetes. Diabetes Obes Metab. 2018;20:1585\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"2212_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1530\/EJE-11-0022","volume":"166","author":"A Vaag","year":"2012","unstructured":"Vaag A, Lund SS. Insulin initiation in patients with type\u00a02 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166:159\u201370.","journal-title":"Eur J Endocrinol"}],"updated-by":[{"DOI":"10.1007\/s12325-022-02349-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02212-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T07:08:04Z","timestamp":1667286484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02212-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02212-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-022-02349-1","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-022-02349-1","URL":"https:\/\/doi.org\/10.1007\/s12325-022-02349-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}